Hansa Biopharma AB (publ) (STO:HNSA)
Sweden · Delayed Price · Currency is SEK 46.68
+3.90 (9.12%)
Sep 2, 2026, 5:29 PM CET
Hansa Biopharma AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 189.46 | 222.27 | 171.32 | 134.09 | 154.53 | 33.88 | |
Revenue Growth | -3.57% | 29.74% | 27.76% | -13.22% | 356.12% | 455.56% |
Cost of Revenue | 81.14 | 83.56 | 83.55 | 63.14 | 38.48 | 15.43 |
Gross Profit | 108.32 | 138.71 | 87.76 | 70.95 | 116.05 | 18.45 |
Selling, General & Admin | 414.52 | 356.55 | 344.27 | 450.49 | 337.86 | 327.27 |
Research & Development | 269.85 | 304.74 | 375.72 | 411.33 | 346.24 | 230.76 |
Other Operating Expenses | 1.48 | - | - | 0.29 | 8.06 | - |
Operating Expenses | 685.85 | 661.28 | 719.99 | 862.11 | 692.17 | 558.03 |
Operating Income | -577.53 | -522.58 | -632.22 | -791.16 | -576.12 | -539.58 |
Interest Expense | -121.19 | -122.49 | -134.08 | -105.52 | -43.67 | -0.69 |
Interest & Investment Income | 13.09 | 7.33 | 20.83 | 28.06 | 8.83 | 0.07 |
Currency Exchange Gain (Loss) | -31.87 | 165.34 | -71.39 | 37.81 | 5.95 | -7.4 |
Other Non Operating Income (Expenses) | -35.44 | - | 12.65 | - | -4.97 | -0.53 |
EBT Excluding Unusual Items | -752.93 | -472.4 | -804.21 | -830.81 | -609.98 | -548.13 |
Merger & Restructuring Charges | -59.45 | -59.45 | - | - | - | - |
Pretax Income | -752.93 | -531.84 | -804.21 | -830.81 | -609.98 | -548.13 |
Income Tax Expense | 2.22 | 2.27 | 3.03 | 0.91 | 1.16 | 0.15 |
Net Income | -755.14 | -534.11 | -807.24 | -831.72 | -611.13 | -548.28 |
Net Income to Common | -755.14 | -534.11 | -807.24 | -831.72 | -611.13 | -548.28 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 98 | 81 | 63 | 53 | 45 | 44 |
Shares Outstanding (Diluted) | 98 | 81 | 63 | 53 | 45 | 44 |
Shares Change | 42.70% | 29.23% | 19.59% | 16.95% | 1.01% | 5.45% |
EPS (Basic) | -7.74 | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 |
EPS (Diluted) | -7.74 | -6.58 | -12.85 | -15.83 | -13.60 | -12.33 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -569.63 | -549.17 | -675 | -755.94 | -506.06 | -483.57 |
Free Cash Flow Per Share | -5.84 | -6.76 | -10.74 | -14.39 | -11.27 | -10.87 |
Gross Margin | 57.17% | 62.41% | 51.23% | 52.91% | 75.10% | 54.47% |
Operating Margin | -304.83% | -235.11% | -369.04% | -590.00% | -372.83% | -1592.71% |
Profit Margin | -398.58% | -240.30% | -471.20% | -620.25% | -395.49% | -1618.40% |
Free Cash Flow Margin | -300.66% | -247.08% | -394.01% | -563.74% | -327.50% | -1427.38% |
EBITDA | -570.37 | -520.07 | -629.67 | -788.33 | -573.71 | -538.06 |
EBITDA Margin | - | -233.99% | - | - | - | - |
D&A For EBITDA | 7.16 | 2.5 | 2.55 | 2.83 | 2.41 | 1.52 |
EBIT | -577.53 | -522.58 | -632.22 | -791.16 | -576.12 | -539.58 |
EBIT Margin | - | -235.11% | - | - | - | - |